Skip to content
Dr. Estela Rodriguez· @Latinamd · X·· 14 hours agoScore70

DELLPHI-305

Body · original

💃🍷 Eating tapas while watching the TOP #lungcancer abstracts roll in from #ESMO26 in Madrid!

🔬 From today’s DeLLphi-305 results with tarlatamab in SCLC to upcoming data on KRAS G12C, EGFR/MET combinations & next-gen ADCs in NSCLC — so much to look forward to!

What are YOU most excited about? 👇

#LungCancer #LCSM #ESMO26 🇪🇸 @myESMO

33 views · 0 likes · 1 repost · 0 replies

Conference abstracts
LBA3matched by Presidential Symposium I

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

https://esmocongress.esmo.org

Source: Dr. Estela Rodriguez · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org